Abstract 5965: Plk1-BRN2 signaling axis drives lineage plasticity in castration-resistant prostate cancer
Abstract Prostate cancer frequently acquires resistance to androgen receptor (AR)-targeted therapies through lineage plasticity, leading to neuroendocrine prostate cancer (NEPC), an aggressive and therapy-resistant subtype. BRN2 (POU3F2) is a key transcription factor that drives this transition and is normally repressed by AR signaling; however, the upstream mechanisms that activate BRN2 during therapy resistance remain poorly defined. We identify Polo-like kinase 1 (Plk1), a mitotic kinase upregulated in advanced disease, as a previously unrecognized upstream regulator of BRN2. Plk1 directly phosphorylates BRN2 at a conserved motif, enhancing its transcriptional activity and promoting downstream neuroendocrine reprogramming. Disruption of this phosphorylation markedly diminishes neuroendocrine marker expression and inhibits cellular plasticity. RNA-seq analysis further revealed suppression of EMT-associated transcriptional programs as a major downstream consequence of impaired BRN2 phosphorylation. In vivo, using a robust NEPC mouse model, inhibition of Plk1-dependent BRN2 activation reprograms tumor histology and molecular phenotype toward an AR-positive prostate adenocarcinoma (ARPC) state, indicating inhibition of lineage plasticity. These findings identify Plk1-mediated BRN2 phosphorylation as a critical driver of neuroendocrine transdifferentiation and highlight the Plk1-BRN2 axis as a promising therapeutic target to prevent NEPC progression in castration-resistant prostate cancer. Citation Format: Fatemeh Seilani, Meng Wu, Jia Peng, Mohammad Esfini Farahani, Xinyi Wang, Jinghui Liu, Yanquan Zhang, Ruixin Wang, Xiaoqi Liu. Plk1-BRN2 signaling axis drives lineage plasticity in castration-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5965.
Authors
- Meng Wu (ORCID: https://orcid.org/0000-0001-7381-5591)
- X. Liu
- Mohammad Esfini Farahani (ORCID: https://orcid.org/0009-0003-0645-3561)
- Xinyi Wang (ORCID: https://orcid.org/0009-0002-6349-8013)
- Jia Peng (ORCID: https://orcid.org/0000-0003-4644-3053)
- Jinghui Liu (ORCID: https://orcid.org/0000-0003-2770-8415)
- Fatemeh Seilani
- Yanquan Zhang
- Ruixin Wang
Institutions
- University of Kentucky (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2026-04-03
- DOI
- https://doi.org/10.1158/1538-7445.am2026-5965
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00